Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor-Reference-Cited by-同舟云学术

Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor

Published:2016-08-24 Issue:3 Volume:2 Page:202-212
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions

Author:

Timmers Maarten¹²,Van Broeck Bianca¹,Ramael Steven³,Slemmon John⁴,De Waepenaert Katja¹,Russu Alberto¹,Bogert Jennifer⁵,Stieltjes Hans¹,Shaw Leslie M.⁶,Engelborghs Sebastiaan²⁷,Moechars Dieder¹,Mercken Marc¹,Liu Enchi⁴,Sinha Vikash⁸,Kemp John¹,Van Nueten Luc¹,Tritsmans Luc¹,Streffer Johannes Rolf¹²

Affiliation:

1. Janssen Research and Development; Janssen Pharmaceutica N.V.; Beerse Belgium

2. Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp; Antwerp Belgium

3. SGS Life Science Services; Antwerp Belgium

4. Janssen Research and Development LLC; La Jolla CA USA

5. Janssen Research and Development LLC; Raritan NJ USA

6. Perelman School of Medicine, University of Pennsylvania; Philadelphia PA USA

7. Department of Neurology and Memory Clinic; Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken; Antwerp Belgium

8. Janssen Research and Development LLC; Titusville NJ USA

Funder

Janssen Research and Development

Janssen Pharmaceutica N.V.